Meningioma and schwannoma management
Meningioma and schwannoma management is a research topic within Epidemiology. Science Explorer counts 35k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the epidemiology, genomic analysis, histological classification, and treatment outcomes of meningiomas, including the use of radiosurgery and surgical management. It also explores the epidemiology and natural history of vestibular schwannomas. The papers cover topics such as DNA methylation-based classification, tumor control, prognostic factors, and long-term follow-up after different treatment modalities.
- Meningiomas
- Radiosurgery
- Genomic Analysis
- Epidemiology
- Histological Classification
- Vestibular Schwannoma
- DNA Methylation
- Tumor Control
- Surgical Management
- Prognostic Factors
- Research works
- 35k fractional, since 1950
- In the world top 10%
- 3.4k per year above
- Top-10% rate
- 9.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +30% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Meningioma and schwannoma management research?
By volume, the United States and China publish the most (1.8k and 675 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.8k works
- 2 China 675 works
- 3 India 443 works
- 4 Japan 427 works
- 5 Germany 306 works
- 6 Italy 305 works
- 7 United Kingdom 211 works
- 8 South Korea 164 works
- 9 Türkiye 160 works
- 10 France 159 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Meningioma and schwannoma management research?
By volume in 2022–2025, Neurological Surgery publishes the most Meningioma and schwannoma management research, followed by Mayo Clinic and Capital Medical University.
By volume, 2022–2025
- 1 Neurological Surgery United States 100 works
- 2 Mayo Clinic United States 44 works
- 3 Capital Medical University China 41 works
- 4 All India Institute of Medical Sciences India 34 works
- 5 Stanford University United States 29 works
- 6 University of California, San Francisco United States 27 works
- 7 Emory University United States 25 works
- 8 Harvard University United States 24 works
- 9 University of Pittsburgh Medical Center United States 24 works
- 10 Mayo Clinic in Florida United States 23 works
Where is Meningioma and schwannoma management research done?
The largest centres of Meningioma and schwannoma management research in 2022–2025 are Beijing (China), Tokyo (Japan), Rockville Centre (United States) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Rockville Centre, Phoenix and Rochester.
Largest cities, 2022–2025
- 1 Beijing China 136 works
- 2 Tokyo Japan 113 works
- 3 Rockville Centre United States 100 works
- 4 Seoul South Korea 91 works
- 5 New York United States 79 works
- 6 Shanghai China 78 works
- 7 Moscow Russia 69 works
- 8 London United Kingdom 66 works
- 9 Istanbul Türkiye 65 works
- 10 Boston United States 64 works
Where it is the local speciality
- Rockville CentreUS · 100.1 works112×
- PhoenixUS · 38.8 works21×
- RochesterUS · 44.1 works18×
Location quotient: how much more of its research is in Meningioma and schwannoma management than the world average.
Where is the best place to study Meningioma and schwannoma management?
Among universities, judged by research, Capital Medical University, University of California, San Francisco and University of Naples Federico II score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Capital Medical University China | 55.5 | 11.2% | 11.6× | 41 | +45.0% |
| 2 | University of California, San Francisco United States | 49.7 | 13.9% | 7.1× | 27 | +41.4% |
| 3 | University of Naples Federico II Italy | 48.9 | 24.4% | 4.7× | 17 | +22.9% |
| 4 | Heidelberg University Germany | 47.0 | 23.4% | 4.0× | 13 | +11.4% |
| 5 | Medical University of Vienna Austria | 46.7 | 13.1% | 7.2× | 13 | +21.4% |
| 6 | Harvard University United States | 46.6 | 16.5% | 3.1× | 24 | +83.0% |
| 7 | All India Institute of Medical Sciences India | 45.9 | 3.0% | 9.1× | 34 | +97.9% |
| 8 | University of Tübingen Germany | 42.9 | 21.7% | 4.2× | 10 | +33.6% |
| 9 | University of Padua Italy | 41.9 | 19.8% | 2.2× | 11 | +124.3% |
| 10 | Icahn School of Medicine at Mount Sinai United States | 41.6 | 10.8% | 4.0× | 12 | +316.9% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Meningioma and schwannoma management research growing?
Output in 2018–2022 was 30% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Meningioma and schwannoma management.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.